NCT05611528View on ClinicalTrials.gov

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

December 27, 2024

Study Completion Date

March 18, 2025

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

Evinacumab

Evinacumab 15 mg/kg administered intravenously every 4 weeks

Trial Locations (1)

G7H 7K9

Ecogene-21, Saguenay

All Listed Sponsors
collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

Daniel Gaudet

OTHER